Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today
Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...
Why Eli Lilly Stock Topped the Market Today
On Friday morning, Novo Nordisk unveiled the latest results from a clinical trial of CagriSema, an investigational drug ...
Novo Nordisk next-gen shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
MM&M12d
Novo Nordisk’s amycretin cuts weight by 22% in early obesity trial
Just over a month after its CagriSema readout disappointed analysts, Novo Nordisk released promising data for its obesity drug amycretin. The Danish pharmaceutical giant ended off the week on a high ...
Yahoo Finance12d
Novo shares climb on early data for dual-acting obesity drug
Amycretin affects the same two targets as a Novo drug called cagrisema that recently missed expectations in a Phase 3 trial, but does so in a single molecule rather than a two-drug combination.
Benzinga.com1mon
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
The Street broadly expected the Redefine-1 trial of CagriSema to show ~25% weight ... selected ACCG-2671 as its lead oral small molecule amylin receptor agonist for obesity and related diseases.
The Motley Fool12d
Why Eli Lilly Stock Topped the Market Today
On Friday morning, Novo Nordisk unveiled the latest results from a clinical trial of CagriSema, an investigational drug leveraging the foundational semaglutide molecule used in Wegovy ...